A BILL 
To mitigate drug shortages and provide incentives for main-
taining, expanding, and relocating the manufacturing of 
active pharmaceutical ingredients, excipients, medical di-
agnostic devices, pharmaceuticals, and personal protec-
tive equipment in the United States, and for other pur-
poses. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
07:43 Jun 14, 2020
H6930
2 
•HR 6930 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Manufacturing API, 
2
Drugs, and Excipients in America Act of 2020’’ or the 
3
‘‘MADE in America Act of 2020’’. 
4
SEC. 2. TABLE OF CONTENTS. 
5
The table of contents of this Act is as follows: 
6
Sec. 1. Short title. 
Sec. 2. Table of contents. 
TITLE I—HEALTH PROVISIONS 
Sec. 101. Report to Congress on barriers to domestic manufacturing of medical 
products and supplies. 
Sec. 102. Enhance intraagency coordination and public health assessment with 
regard to compliance activities. 
Sec. 103. Encouraging international harmonization. 
Sec. 104. Mutual recognition agreements for inspections and review activities. 
Sec. 105. Enhancing transparency of drug facility inspection timelines. 
Sec. 106. Advanced manufacturing technologies program. 
TITLE II—TAX INCENTIVES TO INCREASE DOMESTIC 
PHARMACEUTICAL AND MEDICAL DEVICE PRODUCTION 
Sec. 201. Credit for pharmaceutical and medical device production activities in 
distressed zones. 
TITLE I—HEALTH PROVISIONS 
7
SEC. 101. REPORT TO CONGRESS ON BARRIERS TO DOMES-
8
TIC MANUFACTURING OF MEDICAL PROD-
9
UCTS AND SUPPLIES. 
10
(a) REPORT.—Not later than January 1, 2021, the 
11
Secretary of Health and Human Services (referred to in 
12
this section as the ‘‘Secretary’’) shall submit to the Com-
13
mittee on Energy and Commerce of the House of Rep-
14
resentatives and the Committee on Health, Education, 
15
Labor, and Pensions of the Senate a report on barriers 
16
to domestic manufacturing of active pharmaceutical ingre-
17
07:43 Jun 14, 2020
H6930
3 
•HR 6930 IH
dients, drugs, and devices that are sourced or manufac-
1
tured outside of the United States. 
2
(b) CONTENTS.—Such report shall— 
3
(1) identify factors that limit or otherwise dis-
4
courage the domestic manufacturing of active phar-
5
maceutical ingredients, drugs, and devices that are 
6
currently sourced or manufactured outside of the 
7
United States, including any Federal, State, local, or 
8
Tribal laws and regulations that hinder domestic 
9
manufacturing opportunities; and 
10
(2) recommend specific strategies to overcome 
11
the challenges identified under paragraph (1), in-
12
cluding strategies— 
13
(A) to develop effective incentives for do-
14
mestic manufacturing; and 
15
(B) to make changes to laws or regulations 
16
that hinder domestic manufacturing opportuni-
17
ties. 
18
(c) CONSULTATION.—In carrying out the report 
19
under subsection (a), the Secretary shall consult with— 
20
(1) the Food and Drug Administration, the 
21
Centers for Medicare & Medicaid Services, the De-
22
partment of Defense, the Department of Commerce, 
23
the Department of State, the Department of Vet-
24
07:43 Jun 14, 2020
H6930
4 
•HR 6930 IH
erans Affairs, the Department of Justice, and any 
1
other Federal agencies as appropriate; and 
2
(2) relevant stakeholders, including drug, de-
3
vice, and active pharmaceutical ingredient manufac-
4
turers, and other entities, as appropriate. 
5
(d) DEFINITION.—In this section, the term ‘‘active 
6
pharmaceutical ingredient’’ has the meaning given to such 
7
term in section 207.1 of title 21, Code of Federal Regula-
8
tions (and any successor regulations). 
9
(e) PUBLICATION.—The Secretary shall make the re-
10
port under subsection (a) available on the public website 
11
of the Department of Health and Human Services. 
12
SEC. 102. ENHANCE INTRAAGENCY COORDINATION AND 
13
PUBLIC HEALTH ASSESSMENT WITH REGARD 
14
TO COMPLIANCE ACTIVITIES. 
15
(a) BENEFIT/RISK FRAMEWORK.— 
16
(1) IN
GENERAL.—Paragraph (2) of section 
17
704(b) of the Federal Food, Drug, and Cosmetic Act 
18
(21 U.S.C. 374(b)) is amended by adding at the end 
19
the following: ‘‘The Secretary shall ensure timely 
20
and effective coordination among such offices re-
21
garding the reviews of such report and the align-
22
ment of any feedback regarding such report, and 
23
any corrective or preventive actions in response to 
24
such report, after consideration of the benefits and 
25
07:43 Jun 14, 2020
H6930
5 
•HR 6930 IH
risks to the public health, patient safety, the drug 
1
supply and drug supply chain, and timely patient ac-
2
cess to drugs.’’. 
3
(2) ANNUAL
REPORTING.—Subsection (b) of 
4
section 704 of the Federal Food, Drug, and Cos-
5
metic Act (21 U.S.C. 374) is amended by adding at 
6
the end the following new paragraph: 
7
‘‘(3) On an annual basis, the Secretary shall prepare 
8
a report on the utilization of the framework described in 
9
paragraph (2) and post such report on the public website 
10
of the Food and Drug Administration.’’. 
11
(3) APPLICABILITY.—The amendments made 
12
by paragraphs (1) and (2) shall take effect on the 
13
effective date described in section 3112 of the 
14
CARES Act (Public Law 116–136), after executing 
15
the amendments made by such section 3112, and 
16
shall apply beginning on the date that is 1 year after 
17
the date of enactment of this Act. 
18
(b) PUBLIC MEETING.—The Secretary of Health and 
19
Human Services shall publish in the Federal Register a 
20
notice of a public meeting to be held no later than six 
21
months after the date of enactment of this Act to discuss 
22
and obtain input and recommendations from public stake-
23
holders, including patient advocates, consumers, regulated 
24
industry, and health care providers, regarding the con-
25
07:43 Jun 14, 2020
H6930
6 
•HR 6930 IH
tents of a benefit/risk framework described in section 
1
704(b)(2) of the Federal Food, Drug, and Cosmetic Act, 
2
as amended by subsection (a), that supports a safe, stable, 
3
redundant drug supply chain. 
4
(c) GUIDANCE.—The Secretary of Health and 
5
Human Services shall— 
6
(1) not later than one year after the date of en-
7
actment of this Act, issue draft guidance regarding 
8
the goals and implementation of a benefit/risk 
9
framework described in subsection (b); and 
10
(2) not later than two years after such date of 
11
enactment, issue final guidance with respect to the 
12
implementation of such a framework. 
13
SEC. 
103. 
ENCOURAGING 
INTERNATIONAL 
HARMONI-
14
ZATION. 
15
(a) GAO STUDY.—Not later than one year after the 
16
date of enactment of this Act, the Comptroller General 
17
of the United States shall issue a report evaluating— 
18
(1) the consistency with which the International 
19
Conference on Harmonisation (in this section re-
20
ferred to as ‘‘ICH’’) guidelines on good manufac-
21
turing practices, including ICH Guidelines Q8–11, 
22
are being implemented by drug regulatory authori-
23
ties across countries and international regions; 
24
07:43 Jun 14, 2020
H6930
7 
•HR 6930 IH
(2) whether domestic active pharmaceutical in-
1
gredient manufacturers (including any such contract 
2
manufacturers) are provided sufficient opportunity 
3
to participate with regulatory authorities in the de-
4
velopment of guidelines prior to implementation; 
5
(3) whether divergence from ICH guidelines or 
6
differing regulatory standards or requirements by 
7
drug regulatory authorities across countries and 
8
international regions creates— 
9
(A) inefficiencies in drug manufacturing; 
10
(B) incompatible requirements that can 
11
contribute to or exacerbate drug shortages; and 
12
(C) the most common areas of divergence 
13
between ICH guidelines and regulatory stand-
14
ards and requirements by drug regulatory au-
15
thorities across countries and international re-
16
gions that, if rectified, may reduce the ineffi-
17
ciencies and incompatibilities identified pursu-
18
ant to subparagraphs (A) and (B). 
19
(b) INTERNATIONAL TRAINING PROGRAM.—Not later 
20
than two years after the date of enactment of this Act, 
21
informed by the needs identified in the report issued pur-
22
suant to subsection (a), the Secretary of Health and 
23
Human Services, in conjunction with drug regulatory au-
24
thorities across countries and international regions and 
25
07:43 Jun 14, 2020
H6930
8 
•HR 6930 IH
the ICH, shall develop and implement a training program 
1
for drug regulatory authorities across countries and inter-
2
national regions to promote consistent application of and 
3
reduce divergence from ICH guidelines on good manufac-
4
turing practices. 
5
SEC. 104. MUTUAL RECOGNITION AGREEMENTS FOR IN-
6
SPECTIONS AND REVIEW ACTIVITIES. 
7
(a) MUTUAL RECOGNITION OF INSPECTIONS.—Pur-
8
suant to section 809 of the Federal Food, Drug and Cos-
9
metics Act (21 U.S.C. 384e), the Secretary of Health and 
10
Human Services (in this section referred to as the ‘‘Sec-
11
retary’’) shall establish or expand initiatives for mutual 
12
sharing of review and inspection criteria between drug reg-
13
ulatory authorities across countries and international re-
14
gions, such as through the Pharmaceutical Cooperation 
15
Inspection Scheme, the Mutual Recognition Agreement 
16
with the European Union, and the Australia-Canada- 
17
Singapore-Switzerland Consortium, to— 
18
(1) reduce the potential for duplicative regu-
19
latory evaluation of medical products regulated by 
20
the Food and Drug Administration; and 
21
(2) more constructively allocate appropriations 
22
to the Food and Drug Administration, including 
23
those attributable to user fees, to harmonized regu-
24
latory processes. 
25
07:43 Jun 14, 2020
H6930
9 
•HR 6930 IH
(b) ADDITIONAL COUNTRIES, REGIONS, AND EVAL-
1
UATION.—In carrying out subsection (a), the Secretary 
2
may expand the initiatives to include— 
3
(1) additional countries and geographic regions 
4
with established and competent regulatory frame-
5
works; and 
6
(2) additional types of regulatory evaluation, in-
7
cluding with respect to— 
8
(A) good manufacturing practice inspec-
9
tions; and 
10
(B) approval of changes to the manufac-
11
turing of drugs for which an approval or licen-
12
sure is in effect under section 505 of the Fed-
13
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
14
355) or section 351 of the Public Health Serv-
15
ice Act (42 U.S.C. 262). 
16
(c) IMPLEMENTATION FRAMEWORK.— 
17
(1) PUBLICATION.—Not later than one year 
18
after the date of enactment of this Act, the Sec-
19
retary shall publish an implementation framework 
20
for the agreements to share review and inspection 
21
criteria under subsection (a) on the public website of 
22
the Food and Drug Administration. 
23
(2) CONTENTS.—The implementation frame-
24
work under this subsection shall— 
25
07:43 Jun 14, 2020
H6930
10 
•HR 6930 IH
(A) include the timeline for establishing or 
1
expanding initiatives described in subsection 
2
(a); 
3
(B) describe additional types of regulatory 
4
processes that will become subject to such ini-
5
tiatives; 
6
(C) specify the countries and geographic 
7
regions where such initiatives will be established 
8
or expanded; and 
9
(D) identify additional opportunities and 
10
challenges for expanding mutual recognition 
11
agreements in drug and biologic regulation. 
12
(d) ANNUAL REPORTING.— 
13
(1) IN GENERAL.—Not later than the end of 
14
calendar year 2020 and annually thereafter, the Sec-
15
retary shall publish a report on the public website of 
16
the Food and Drug Administration on the utilization 
17
of agreements described in subsection (c)(1) in the 
18
previous fiscal year. 
19
(2) CONTENTS.—The report under paragraph 
20
(1) shall include each of the following: 
21
(A) The total number of establishments 
22
that are registered under section 510(i) of the 
23
Federal Food, Drug, and Cosmetic Act (21 
24
U.S.C. 360) and located outside of the United 
25
07:43 Jun 14, 2020
H6930
11 
•HR 6930 IH
States, and of these establishments, the number 
1
in each region of interest. 
2
(B) The total number of inspections con-
3
ducted at establishments described in subpara-
4
graph (A). 
5
(C) Of the inspections described in sub-
6
paragraph (B), the total number of inspections 
7
in each of region of interest. 
8
(D) Of the inspections in each region of in-
9
terest reported pursuant to subparagraph (C), 
10
the number of inspections in each FDA inspec-
11
tion category. 
12
(E) Of the number of inspections reported 
13
under each of subparagraphs (B), (C), and 
14
(D)— 
15
(i) the number of inspections which 
16
have been conducted pursuant to an agree-
17
ment described in subsection (c)(1); and 
18
(ii) the number of inspections which 
19
have been conducted by employees or other 
20
agents of the Food and Drug Administra-
21
tion. 
22
(3) DEFINITIONS.—In this subsection: 
23
(A) The term ‘‘region of interest’’ refers to 
24
China, India, the European Union, and any 
25
07:43 Jun 14, 2020
H6930
12 
•HR 6930 IH
other geographic region as determined appro-
1
priate by the Secretary. 
2
(B) The term ‘‘FDA inspection category’’ 
3
means refers to the following inspection cat-
4
egories: 
5
(i) Inspections to support an approval 
6
of a drug under section 505 of the Federal 
7
Food, Drug, and Cosmetic Act (21 U.S.C. 
8
355) or section 351 of the Public Health 
9
Service Act (42 U.S.C. 262). 
10
(ii) Good manufacturing practice in-
11
spections. 
12
(iii) For-cause inspections. 
13
SEC. 105. ENHANCING TRANSPARENCY OF DRUG FACILITY 
14
INSPECTION TIMELINES. 
15
Section 902 of the FDA Reauthorization Act of 2017 
16
(21 U.S.C. 355 note) is amended to read as follows: 
17
‘‘SEC. 902. ANNUAL REPORT ON INSPECTIONS. 
18
‘‘Not later than March 1 of each year, the Secretary 
19
of Health and Human Services shall post on the public 
20
website of the Food and Drug Administration information 
21
related to inspections of facilities necessary for approval 
22
of a drug under subsection (c) or (j) of section 505 of 
23
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
24
355), approval of a device under section 515 of such Act 
25
07:43 Jun 14, 2020
H6930
13 
•HR 6930 IH
(21 U.S.C. 360e), or clearance of a device under section 
1
510(k) of such Act (21 U.S.C. 360(k)) that were con-
2
ducted during the previous calendar year. Such informa-
3
tion shall include the following: 
4
‘‘(1) The median time following a request from 
5
staff of the Food and Drug Administration review-
6
ing an application or report to the beginning of the 
7
inspection, and the median time from the beginning 
8
of an inspection to the issuance of a report pursuant 
9
to section 704(b) of the Federal Food, Drug, and 
10
Cosmetic Act (21 U.S.C. 374(b)), including— 
11
‘‘(A) the median time for drugs described 
12
in 505(j)(11)(A)(i) of the Federal Food, Drug, 
13
and Cosmetic Act (21 U.S.C. 355(j)(11)(A)(i)); 
14
‘‘(B) the median time for drugs described 
15
in section 506C(a) of such Act (21 U.S.C. 
16
356c(a)) only; and 
17
‘‘(C) the median time for drugs on the 
18
drug shortage list in effect under section 506E 
19
of such Act (21 U.S.C. 356f). 
20
‘‘(2) The median time from the issuance of a 
21
report pursuant to such section 704(b) to the send-
22
ing of a warning letter, issuance of an import alert, 
23
or holding of a regulatory meeting for inspections 
24
for which the Secretary concluded that regulatory or 
25
07:43 Jun 14, 2020
H6930
14 
•HR 6930 IH
enforcement action was indicated, including the me-
1
dian time for each category of drugs listed in sub-
2
paragraphs (A) through (C) of paragraph (1). 
3
‘‘(3) The median time from the sending of a 
4
warning letter, issuance of an import alert, or hold-
5
ing of a regulatory meeting to resolution of the regu-
6
latory or enforcement action indicated for inspec-
7
tions for which the Secretary concluded that such 
8
action was indicated. 
9
‘‘(4) The number of times that a facility was 
10
issued a report pursuant to such section 704(b) and 
11
approval of an application was delayed due to the 
12
issuance of a withhold recommendation, including 
13
the number of such times for each category of drugs 
14
listed in subparagraphs (A) through (C) of para-
15
graph (1).’’. 
16
SEC. 106. ADVANCED MANUFACTURING TECHNOLOGIES 
17
PROGRAM. 
18
Subchapter A of chapter V of the Federal Food, 
19
Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amend-
20
ed by adding at the end the following: 
21
‘‘SEC. 524B. ADVANCED MANUFACTURING TECHNOLOGIES 
22
PROGRAM. 
23
‘‘(a) IN GENERAL.—Not later than 1 year after the 
24
date of enactment of the Manufacturing API, Drugs, and 
25
07:43 Jun 14, 2020
H6930
15 
•HR 6930 IH
Excipients in America Act of 2020, the Secretary shall 
1
continue in effect the program to evaluate new drug manu-
2
facturing technologies that are included in an application, 
3
or supplement to an application, for a drug under sub-
4
section (b) or (j) of section 505 of this Act or for a biologi-
5
cal product submitted under subsection (a) or (k) of sec-
6
tion 351 of the Public Health Service Act. 
7
‘‘(b) DESIGNATION.—The Secretary shall designate a 
8
method of manufacturing a drug as an advanced manufac-
9
turing technology under this section if the drug manufac-
10
turer demonstrates that such technology is likely to— 
11
‘‘(1) prevent or resolve a drug shortage; 
12
‘‘(2) maintain an adequate supply of critical 
13
medications for national emergencies; or 
14
‘‘(3) promote the adoption of innovative ap-
15
proaches to drug product design and manufacturing. 
16
‘‘(c) CONSULTATION.—If the Secretary designates a 
17
method of manufacturing as an advanced manufacturing 
18
technology under this section, the Secretary shall take ac-
19
tions to expedite the development and implementation of 
20
such method of manufacture for purposes of approval of 
21
the application under subsection (c) or (j) of section 505 
22
of this Act or subsection (a) or (k) of section 351 of the 
23
Public Health Service Act, which may include, as appro-
24
priate— 
25
07:43 Jun 14, 2020
H6930
16 
•HR 6930 IH
‘‘(1) holding meetings between the sponsor of 
1
the application and appropriate Food and Drug Ad-
2
ministration staff throughout the development of the 
3
technology; 
4
‘‘(2) providing timely advice to, and interactive 
5
communication with, the sponsor regarding the de-
6
velopment of the technology; and 
7
‘‘(3) involving senior managers and experienced 
8
staff of the Food and Drug Administration, as ap-
9
propriate, in a collaborative, cross-disciplinary review 
10
of the method of manufacturing. 
11
‘‘(d) EVALUATION
OF
AN ADVANCED MANUFAC-
12
TURING TECHNOLOGY.— 
13
‘‘(1) PACKAGE.—A sponsor who receives des-
14
ignation of an advanced manufacturing technology 
15
under this section shall provide the Secretary with a 
16
package of scientific evidence supporting the imple-
17
mentation of the advanced manufacturing technology 
18
in a particular context-of-use. 
19
‘‘(2) EVALUATION.—Within 90 days of receiv-
20
ing the package, the Secretary shall determine 
21
whether a designated advanced manufacturing tech-
22
nology is validated for the proposed context of use 
23
based on the scientific merit the supporting evidence 
24
provided by the sponsor. 
25
07:43 Jun 14, 2020
H6930
17 
•HR 6930 IH
‘‘(3) EFFECT OF APPROVAL.—Upon approval, 
1
the same sponsor may rely upon the advanced man-
2
ufacturing technology for use across multiple manu-
3
facturing product lines within the same context-of- 
4
use without having to re-submit data to the Sec-
5
retary validating the underlying technology. 
6
‘‘(e) IMPLEMENTATION AND REPORTING.— 
7
‘‘(1) PUBLIC
MEETING.—The Secretary shall 
8
publish in the Federal Register a notice of a public 
9
meeting to be held no later than 1 year after the 
10
date of enactment of the Manufacturing API, 
11
Drugs, and Excipients in America Act of 2020 to 
12
discuss and obtain input and recommendations from 
13
stakeholders regarding the goals and scope of, and 
14
a suitable framework and procedures and require-
15
ments for, the program under this section. 
16
‘‘(2) 
PROGRAM
GUIDANCE.—The 
Secretary 
17
shall— 
18
‘‘(A) not later than 1 year after the date 
19
of enactment of the Manufacturing API, Drugs, 
20
and Excipients in America Act of 2020, issue 
21
draft guidance regarding the goals and imple-
22
mentation of the program under this section; 
23
and 
24
07:43 Jun 14, 2020
H6930
18 
•HR 6930 IH
‘‘(B) not later than 2 years after the date 
1
of enactment of the Manufacturing API, Drugs, 
2
and Excipients in America Act of 2020, issue 
3
final guidance with respect to the implementa-
4
tion of such program. 
5
‘‘(3) REPORT.—The Secretary shall make avail-
6
able on the public website of the Food and Drug Ad-
7
ministration an annual report on the progress of the 
8
program under this section.’’. 
9
TITLE II—TAX INCENTIVES TO 
10
INCREASE DOMESTIC PHAR-
11
MACEUTICAL AND MEDICAL 
12
DEVICE PRODUCTION 
13
SEC. 201. CREDIT FOR PHARMACEUTICAL AND MEDICAL 
14
DEVICE PRODUCTION ACTIVITIES IN DIS-
15
TRESSED ZONES. 
16
(a) IN GENERAL.—Subpart D of part IV of sub-
17
chapter A of chapter 1 of the Internal Revenue Code of 
18
1986 is amended by adding at the end the following new 
19
section: 
20
‘‘SEC. 45U. DISTRESSED ZONE PHARMACEUTICAL AND MED-
21
ICAL DEVICE PRODUCTION CREDIT. 
22
‘‘(a) IN GENERAL.—For purposes of section 38, the 
23
distressed zone pharmaceutical and medical device produc-
24
tion credit for the taxable year shall be an amount equal 
25
07:43 Jun 14, 2020
H6930
19 
•HR 6930 IH
to 30 percent of the qualified production activity expendi-
1
tures of the taxpayer for the taxable year. 
2
‘‘(b) QUALIFIED PRODUCTION ACTIVITY EXPENDI-
3
TURES.—For purposes of this section— 
4
‘‘(1) IN GENERAL.—The term ‘qualified produc-
5
tion activity expenditures’ means— 
6
‘‘(A) wages paid or incurred to an em-
7
ployee of the taxpayer for services performed by 
8
such employee in the conduct of a qualified 
9
pharmaceutical or diagnostic medical device 
10
production business in a distressed zone (but 
11
only if the employee’s principal place of employ-
12
ment is in a distressed zone), or 
13
‘‘(B) amounts paid or incurred for any 
14
tangible personal property (whether or not oth-
15
erwise properly chargeable to capital account) 
16
used in the conduct of a qualified pharma-
17
ceutical or medical device production business 
18
in a distressed zone (but only if the primary use 
19
of such property is in a distressed zone). 
20
‘‘(2) QUALIFIED PHARMACEUTICAL OR MEDICAL 
21
DEVICE PRODUCTION BUSINESS.— 
22
‘‘(A) IN
GENERAL.—The term ‘qualified 
23
pharmaceutical or medical device production 
24
business’ means the trade or business of pro-
25
07:43 Jun 14, 2020
H6930
20 
•HR 6930 IH
ducing pharmaceuticals, excipients, active phar-
1
maceutical ingredients, medical diagnostic de-
2
vices, or personal protective equipment. 
3
‘‘(B) ACTIVE
PHARMACEUTICAL
INGRE-
4
DIENT.—The term ‘active pharmaceutical ingre-
5
dients’ has the meaning given to such term in 
6
section 207.1 of title 21, Code of Federal Regu-
7
lations (and any successor regulations). 
8
‘‘(C) EXCIPIENT.—The term ‘excipient’— 
9
‘‘(i) means any inactive ingredient 
10
that is intentionally added to a pharma-
11
ceutical that is not intended to exert thera-
12
peutic effects at the intended dosage, other 
13
than by acting to improve product delivery; 
14
and 
15
‘‘(ii) includes any such filler, extend-
16
ers, diluent, wetting agent, solvent, emulsi-
17
fier, 
preservative, 
flavor, 
absorption 
18
enhancer, sustained release matrix, and 
19
coloring agent. 
20
‘‘(D) MEDICAL DIAGNOSTIC DEVICE.—The 
21
term ‘medical diagnostic device’ means any de-
22
vice (as defined in section 201(h) of the Federal 
23
Food, Drug, and Cosmetic Act) intended for 
24
07:43 Jun 14, 2020
H6930
21 
•HR 6930 IH
use in the diagnosis of disease or other condi-
1
tions. 
2
‘‘(E) 
PERSONAL
PROTECTIVE
EQUIP-
3
MENT.—The term ‘personal protective equip-
4
ment’ means— 
5
‘‘(i) any device (as defined in section 
6
201(h) of the Federal Food, Drug, and 
7
Cosmetic Act) that is a face mask, filtering 
8
facepiece respirator, face shield, surgical 
9
mask, gown, other apparel, or glove that is 
10
intended for a medical purpose; and 
11
‘‘(ii) any particulate filtering air puri-
12
fying respiratory protective device that is 
13
approved by the National Institute for Oc-
14
cupational Safety and Health under part 
15
84 of title 42, Code of Federal Regulations 
16
(or successor regulations). 
17
‘‘(F) PHARMACEUTICAL.—The term ‘phar-
18
maceutical’— 
19
‘‘(i) means any drug (as defined in 
20
section 201 of the Federal Food, Drug, 
21
and Cosmetic Act); and 
22
‘‘(ii) includes a biological product (as 
23
defined in section 351 of the Public Health 
24
Service Act). 
25
07:43 Jun 14, 2020
H6930
22 
•HR 6930 IH
‘‘(3) CERTAIN HEALTH PLAN EXPENSES TREAT-
1
ED AS WAGES.— 
2
‘‘(A) IN GENERAL.—For purposes of para-
3
graph (1), the term ‘wages’ shall include so 
4
much of the eligible employer’s qualified health 
5
plan expenses as are properly allocable to such 
6
wages. 
7
‘‘(B) 
QUALIFIED
HEALTH
PLAN
EX-
8
PENSES.—For purposes of this paragraph, the 
9
term ‘qualified health plan expenses’ means 
10
amounts paid or incurred by the eligible em-
11
ployer to provide and maintain a group health 
12
plan (as defined in section 5000(b)(1)), but 
13
only to the extent that such amounts are ex-
14
cluded from the gross income of employees by 
15
reason of section 106(a) of such Code. 
16
‘‘(C) ALLOCATION RULES.—For purposes 
17
of this paragraph, qualified health plan ex-
18
penses shall be allocated to qualified wages in 
19
such manner as the Secretary may prescribe. 
20
Except as otherwise provided by the Secretary, 
21
such allocation shall be treated as properly 
22
made if made on the basis of being pro rata 
23
among employees and pro rata on the basis of 
24
07:43 Jun 14, 2020
H6930
23 
•HR 6930 IH
periods of coverage (relative to the periods to 
1
which such wages relate). 
2
‘‘(4) DISTRESSED ZONE.—The term ‘distressed 
3
zone’ means a population census tract— 
4
‘‘(A) which has been designated as a quali-
5
fied opportunity zone under section 1400Z–1, 
6
and 
7
‘‘(B) which has a poverty rate in excess of 
8
30 percent for the calendar year prior to the 
9
calendar year that includes the date of enact-
10
ment of this section. 
11
‘‘(c) SPECIAL RULES.— 
12
‘‘(1) REDUCTION IN BASIS.—If a credit is de-
13
termined under this section with respect to any 
14
property by reason of any qualified production activ-
15
ity expenditures described in subsection (b)(1)(B), 
16
the basis of such property shall be reduced by the 
17
amount of the credit so determined. 
18
‘‘(2) COORDINATION WITH OTHER CREDITS.— 
19
Any qualified production activity expenditures taken 
20
into account in determining the amount of the credit 
21
under subsection (a) shall not be taken into account 
22
in determining a credit under any other provision of 
23
this chapter. 
24
07:43 Jun 14, 2020
H6930
24 
•HR 6930 IH
‘‘(3) LIMITATION ON WAGES TAKEN INTO AC-
1
COUNT.—The amount of wages taken into account 
2
under subsection (a) with respect to any employee 
3
shall not exceed an amount equal to the contribution 
4
and benefit base in effect under section 230 of the 
5
Social Security Act for the calendar year in which 
6
the taxable year begins.’’. 
7
(b) CREDIT ALLOWED AGAINST ALTERNATIVE MIN-
8
IMUM TAX.—Section 38(c)(4)(B) of such Code is amended 
9
by redesignating clauses (x), (xi), and (xii) as clauses (xi), 
10
(xii), and (xiii), respectively and by inserting after clause 
11
(ix) the following new clause: 
12
‘‘(x) the credit determined under sec-
13
tion 45U,’’. 
14
(c) SPECIAL RULE FOR CONTROLLED FOREIGN COR-
15
16
adding at the end the following new paragraph: 
17
‘‘(4) SPECIAL FOR CONTROLLED FOREIGN COR-
18
WITH
DISTRESSED
ZONE
PHARMA-
19
CEUTICAL AND MEDICAL DEVICE EXPENDITURES.— 
20
The amount of foreign taxes deemed paid by a do-
21
mestic corporation under paragraph (1) (determined 
22
without regard to this paragraph) shall be increased 
23
by an amount equal to the lesser of— 
24
‘‘(A) the excess of— 
25
07:43 Jun 14, 2020
H6930
25 
•HR 6930 IH
‘‘(i) the amount calculated with re-
1
spect to such corporation under paragraph 
2
(1) (determined without regard to this 
3
paragraph and by substituting ‘100 per-
4
cent’ for ‘80 percent’), over 
5
‘‘(ii) the amount calculated with re-
6
spect to such corporation under paragraph 
7
(1) (determined without regard to this 
8
paragraph), or 
9
‘‘(B) an amount equal to 15 percent of the 
10
qualified production activity expenditures (as 
11
defined in section 45U(b)(1)) of the controlled 
12
foreign corporation for the taxable year of the 
13
foreign corporation ending in or with the tax-
14
able year of the domestic corporation.’’. 
15
(d) DENIAL OF DEDUCTION.—Section 280C of such 
16
Code is amended by adding at the end the following new 
17
subsection: 
18
‘‘(i) DISTRESSED
ZONE
PHARMACEUTICAL
AND 
19
MEDICAL DEVICE PRODUCTION CREDIT.—No deduction 
20
shall be allowed for that portion of the qualified produc-
21
tion activity expenditures (as defined in section 45U(b)) 
22
otherwise allowable as a deduction for the taxable year 
23
which is equal to the amount of the distressed zone phar-
24
07:43 Jun 14, 2020
H6930
26 
•HR 6930 IH
maceutical and medical device production credit deter-
1
mined for such taxable year under section 45U(a).’’. 
2
(e) PART OF GENERAL BUSINESS CREDIT.—Section 
3
38(b) of such Code is amended by striking ‘‘plus’’ at the 
4
end of paragraph (32), by striking the period at the end 
5
of paragraph (33) and inserting ‘‘, plus’’, and by adding 
6
at the end the following new paragraph: 
7
‘‘(34) the distressed zone pharmaceutical and 
8
medical device production credit determined under 
9
section 45U(a).’’. 
10
(f) CLERICAL AMENDMENT.—The table of sections 
11
for subpart D of part IV of subchapter A of chapter 1 
12
is amended by adding at the end the following new item: 
13
‘‘Sec. 45U. Distressed zone pharmaceutical and medical device production cred-
it.’’. 
(g) EFFECTIVE DATE.—The amendments made by 
14
this section shall apply to amounts paid or incurred after 
15
the date of the enactment of this Act. 
16
Æ 
07:43 Jun 14, 2020
H6930
